Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanni Zhu

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
Cell Reports. Medicine|November 29, 2021
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapyYan-Ruide Li, Yang Zhou, Yu Jeong Kim, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Cell Stem Cell|September 10, 2019
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for CancerYanni Zhu, Drake J Smith, Yang Zhou, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
Cell Reports. Medicine|November 29, 2021
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapyYan-Ruide Li, Yang Zhou, Yu Jeong Kim, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Cell Stem Cell|September 10, 2019
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for CancerYanni Zhu, Drake J Smith, Yang Zhou, et al.
Pageof 5